Trial Profile

The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use

Most Recent Events

19 Apr 2021 Planned End Date changed from 1 Apr 2022 to 1 Jan 2028.
04 Jun 2019 Results assessing HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
11 Jan 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com